Loading organizations...
§ Venture Capital · Cambridge, MA, USA
Venture capital firm investing in and creating early-stage and growth-stage companies in healthcare and technology sectors.
F-Prime Capital Partners is a venture capital firm based in Cambridge, Massachusetts, that invests in early-stage and growth-stage companies across the healthcare and technology sectors. Operating as an independent subsidiary of Fidelity Investments, the firm utilizes internal capital to fund innovations without the pressure of external fundraising. The organization currently manages $5.3 billion in assets under management and maintains a global portfolio of more than 370 companies operating across the Americas, Europe, and Asia. Additionally, the firm has directly created or co-created over 30 companies from scratch by pairing academic researchers with experienced management teams. Notable investments within their active portfolio include prominent technology and healthcare enterprises such as Beam Therapeutics, Denali Therapeutics, Benchling, Flywire, and Toast. The firm was originally founded in 1969 as Fidelity Ventures by its corporate parent organization, Fidelity Investments.
Key people at F-Prime Capital Partners.
# High-Level Overview
F-Prime Capital is a global venture capital firm with over 50 years of investment history, managing $4.5 billion in assets across a portfolio of more than 370 companies[1][2]. As a division of Fidelity Investments, the firm operates with the capital flexibility and long-term perspective of a major financial institution while maintaining the agility and mission-driven focus of a specialized venture investor[5].
The firm's investment philosophy centers on backing exceptional teams across healthcare and technology sectors at any stage of their growth—from pre-seed through late-stage rounds[1][2]. F-Prime's mission extends beyond financial returns; the firm emphasizes clinical outcomes and real-world impact, seeking to invest in companies that directly shape the future of medicine and technology[2]. This dual focus on ROI and transformational impact distinguishes F-Prime from purely financial venture investors. The firm operates across multiple geographies including North America, Europe, Latin America, China, Japan, India, and Israel, giving it one of the broadest international reaches among venture firms[2].
F-Prime Capital's roots trace back through Fidelity Investments' venture capital operations, which began in 1969[5]. The firm has evolved over more than 50 years into a specialized healthcare and technology investor, with a notable distinction: F-Prime has founded or co-founded over 30 companies itself, rather than solely investing in external entrepreneurs[2]. This founder mentality reflects the firm's deep operational expertise and willingness to build solutions alongside its portfolio companies.
The firm's structure as a Fidelity division provides a unique advantage—it invests Fidelity's own capital rather than managing external limited partner funds, eliminating the pressure to constantly raise new capital[5]. This model allows F-Prime to take longer-term views on investments and maintain consistent support for portfolio companies through market cycles. The firm is led by Stephen Knight, M.D., President & Managing Partner, whose medical background exemplifies F-Prime's composition of investors, engineers, doctors, and scientists[2].
Unlike many venture firms that specialize in specific funding stages, F-Prime backs exceptional teams at any point in their journey—from pre-seed through late-stage growth[1][2]. This flexibility allows the firm to maintain long-term relationships with founders and provide continuity of support.
Operating as a division of Fidelity Investments provides F-Prime with substantial dry powder and the ability to make patient capital decisions without external fundraising pressures[5]. This structural advantage enables longer investment horizons and more strategic portfolio construction.
The firm deliberately assembles teams of investors, engineers, physicians, operators, and scientists rather than purely financial professionals[2][4]. This diversity of expertise translates into meaningful operational guidance beyond capital deployment—the firm provides strategic mentorship, networking opportunities, and hands-on operational support to portfolio companies[1].
F-Prime's track record of founding or co-founding over 30 companies demonstrates a willingness to build solutions from scratch[2]. This founder experience informs how the firm partners with entrepreneurs and what operational challenges it can help navigate.
Through partnerships with sister fund Eight Roads, F-Prime maintains a truly global presence while operating through small, local teams in key markets[2]. This structure allows the firm to provide international perspective and leverage worldwide resources without losing the responsiveness of local expertise.
F-Prime operates at the intersection of two powerful secular trends: the digitization and transformation of healthcare, and the acceleration of frontier technologies like artificial intelligence, robotics, and distributed systems[1][4]. The firm's portfolio spans therapeutics, medtech, health IT, enterprise software, fintech, and frontier tech—positioning it to capture value across multiple waves of innovation[2].
The venture capital industry has increasingly bifurcated between mega-funds focused on late-stage scaling and early-stage specialists. F-Prime's stage-agnostic model and Fidelity backing allow it to operate across this spectrum, effectively bridging the gap and providing continuity for founders. This positioning becomes increasingly valuable as companies require sustained capital and expertise across their lifecycle.
Healthcare innovation specifically benefits from F-Prime's approach. The sector demands both deep scientific expertise and operational sophistication—understanding regulatory pathways, clinical outcomes, and commercialization challenges. By combining physicians, scientists, and operators on its team, F-Prime can provide guidance that purely financial investors cannot. The firm's emphasis on clinical outcomes alongside ROI reflects a market reality: healthcare investors who ignore clinical efficacy ultimately underperform financially[2].
The firm's global reach also positions it to capture innovation flows across geographies. While Silicon Valley remains a hub, breakthrough science and technology increasingly emerges from China, Israel, India, and Europe. F-Prime's presence across these regions allows it to identify and support companies regardless of origin.
F-Prime Capital represents a distinctive model in venture capital: a patient, mission-driven investor with institutional backing and global reach. The firm's willingness to invest at any stage, combined with its multidisciplinary team and founder mentality, creates a competitive advantage in supporting transformational companies through their full lifecycle.
Looking forward, F-Prime's influence will likely expand as healthcare and technology continue converging. The firm's portfolio already reflects this trend—companies combining AI with drug discovery, robotics with healthcare logistics, and blockchain with financial infrastructure. As regulatory environments evolve and capital becomes more selective, investors who can provide both capital and operational expertise will outperform.
The key question for F-Prime's future is whether its stage-agnostic model remains sustainable as mega-funds increasingly dominate late-stage rounds. The firm's answer appears to be deepening its operational value-add and maintaining the founder-operator mentality that allows it to build alongside entrepreneurs rather than simply write checks. In a venture landscape increasingly crowded with capital but scarce in genuine expertise, that positioning should prove durable.
Key people at F-Prime Capital Partners.
F-Prime Capital Partners has more than 26 tracked investments across 25 companies. The latest tracked deal is $775.0M Series A in R1 Therapeutics in March 2026.
